Top
Summary
All studies
Mortality
Hospitalization
Serious outcomes
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All atovaquone studies
..
Feedback
Home
c19early.org COVID-19 treatment researchAtovaquoneAtovaquone (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 atovaquone studies

Home
@CovidAnalysis
All
Studies
Feedback
All studies   Mortality   Hospitalization   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -39% 1 60 Improvement, Studies, Patients Relative Risk Mortality -39% 1 60 Hospitalization 16% 1 60 RCTs -39% 1 60 Late -39% 1 60 Atovaquone for COVID-19 c19early.org May 2025 Favorsatovaquone Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] death 6/41 2/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Late treatment -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk All studies -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk 1 atovaquone COVID-19 study c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Effect extraction pre-specified(most serious outcome) Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] 6/41 2/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Late treatment -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk All studies -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk 1 atovaquone COVID-19 mortality result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) 16% 0.84 [0.70-1.01] hosp. time 41 (n) 19 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.069 Late treatment 16% 0.84 [0.70-1.01] 41 (n) 19 (n) 16% lower risk All studies 16% 0.84 [0.70-1.01] 41 (n) 19 (n) 16% lower risk 1 atovaquone COVID-19 hospitalization result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.069 Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] death 6/41 2/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Late treatment -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk All studies -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk 1 atovaquone COVID-19 serious outcome c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Effect extraction pre-specified(most serious outcome) Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] death 6/41 2/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Late treatment -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk All studies -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk 1 atovaquone COVID-19 Randomized Controlled Trial c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Effect extraction pre-specified(most serious outcome) Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] 6/41 2/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Late treatment -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk All studies -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk 1 atovaquone COVID-19 RCT mortality result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] death 6/41 2/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Late treatment -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk All studies -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk 1 atovaquone COVID-19 peer reviewed studies c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Effect extraction pre-specified(most serious outcome) Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] death 6/41 2/19 Improvement, RR [CI] Treatment Control Jain (DB RCT) 20% 0.80 [0.42-1.52] no improv. 15/40 8/17 Jain (DB RCT) 15% 0.85 [0.71-1.02] no improv. 33/41 18/19 Jain (DB RCT) 16% 0.84 [0.70-1.01] hosp. time 41 (n) 19 (n) Atovaquone COVID-19 outcomes c19early.org May 2025 Favors atovaquone Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0